Aeon closes funding round and acquires Aware Health’s assets
Switzerland-based preventive healthcare company Aeon has closed its seed extension and acquired the core assets of Aware Health, the Germany-based blood diagnostics platform.
Aeon develops AI-powered whole-body health check-ups and is the first European platform to offer a continuous, longitudinal health picture by combining whole-body imaging with recurring blood diagnostics in a single product.
The company’s AI turns this data into personalised risk protection, with records updated every quarter.
The system combines MRI’s one-off structural insights with the continuous biological signals from recurring blood tests, providing both a snapshot and long-term trends. Aeon’s AI models detect patterns, flag deviations early, and predict individual health risks before they develop into disease.
Today, more than 90% of Aeon check-ups surface findings customers can act on, with a significant finding rate of 15.4%.
“We are redefining preventive care by shifting it from reaction to action,” said Tim Seithe, Founder and CEO of Aeon. “Imaging tells you where you are. Blood diagnostics tell you where you are heading. AI is what connects the two into prediction. The acquisition of Aware Health accelerates that vision by two years, and this round gives us everything we need to execute.”
“Aeon is building something genuinely new in European healthcare,” said Rupa Popat, Founding and Managing Partner at Araya Ventures. “The combination of imaging, recurring blood diagnostics, and AI creates a longitudinal health picture that no other platform in Europe offers. We are proud to back Tim and the team at this moment.”
This seed extension brings Aeon’s total seed funding to over $14 million. The round was co-led by Araya Ventures with participation from existing investors Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital, and Bigwave Capital, and funds the integration of Aware Health’s technology and team alongside Aeon’s accelerated European roadmap.
Alongside the funding, Aeon has hired Pablo Tano as AI Lead, an expert in reinforcement learning in the brain. He will lead development of the platform’s intelligent layer: AI models that read across imaging, blood biomarkers, and genetic data to deliver personalised risk prediction and individually tailored health interventions.
Aeon also acquired Aware Health’s blood diagnostics platform, combining a fully regulated diagnostics stack with live laboratory integrations and a network of more than 45 blood-draw locations. The platform offered more than 100 biomarkers across a wide range of preventive health panels and served nearly 10,000 active customers.
For Aeon’s AI roadmap, the acquisition adds a critical asset: a longitudinal biomarker dataset built from recurring testing — the raw material needed to train predictive health models.
Ferdinand Schmidt-Thomé, co-founder of Aware Health, said: “The acquisition gives what we built the opportunity to continue growing as part of a broader preventive-health offering. The combination with whole-body imaging and Aeon’s AI genuinely changes what preventive health looks like in Europe.”
Customer data will only be transferred with each customer’s explicit individual consent and in accordance with GDPR.
For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.
